Meta-Analyses After Avandia: FDA Hopes To Set Standards And Controls
This article was originally published in RPM Report
Executive Summary
FDA is working on a guidance for meta-analysis to support safety reviews, and it clearly hopes to have an impact beyond the walls of White Oak.
You may also be interested in...
The Meta-Physics Of Meta-Analysis: US FDA’s Curious Framing Of New Safety Guidance
Long delayed guidance on meta-analysis “will assist sponsors of drug and biological products in designing safety meta-analyses of randomized controlled trials using best practices,” FDA Commissioner says. True – but is that really the point?
Drug Safety Meta-Analyses: US FDA Emphasizes Trial Quality Over Quantity
Three years overdue, agency draft guidance seeks to inject a threshold level of rigor into meta-analyses of randomized, controlled trials to evaluate drug safety and proposes a three-tiered hierarchy of evidence against which FDA will evaluate such studies for regulatory decision-making purposes.
FDA Polled Review Staff On Avandia REMS Changes
Decision to replace the rosiglitazone REMS’ distribution restrictions with prescriber training reflected a consensus opinion shared by leadership in three CDER offices, despite a poll of reviewers who participated in a June advisory committee meeting and favored eliminating the risk management program.